Wei Chang Zhou
Direktor/Vorstandsmitglied bei WUXI BIOLOGICS (CAYMAN) INC.
Vermögen: 714 532 $ am 30.06.2024
Aktive Positionen von Wei Chang Zhou
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
WUXI BIOLOGICS (CAYMAN) INC. | Direktor/Vorstandsmitglied | 01.05.2016 | - |
Technik-/Wissenschafts-/F&E-Leiter | 01.11.2016 | 31.03.2024 | |
WUXI XDC CAYMAN INC. | Direktor/Vorstandsmitglied | 01.12.2020 | - |
Karriereverlauf von Wei Chang Zhou
Ehemalige bekannte Positionen von Wei Chang Zhou
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | 01.03.2008 | 01.12.2012 |
PDL BIOPHARMA, INC. | Direktor/Vorstandsmitglied | 01.10.2002 | 01.02.2008 |
MERCK & CO., INC. | Corporate Officer/Principal | 01.05.1994 | 01.10.2002 |
Ausbildung von Wei Chang Zhou
Jiangxi University of Science & Technology | Undergraduate Degree |
University of Hannover | Doctorate Degree |
Statistik
International
China | 4 |
Vereinigte Staaten | 4 |
Deutschland | 2 |
Operativ
Director/Board Member | 4 |
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
WUXI BIOLOGICS (CAYMAN) INC. | Health Technology |
MERCK & CO., INC. | Health Technology |
WUXI XDC CAYMAN INC. | Commercial Services |
Private Unternehmen | 2 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
PDL BioPharma, Inc.
PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
- Börse
- Insiders
- Wei Chang Zhou
- Erfahrung